Fig. 5: ORACLE as a summary metric of lung cancer evolution.
a, Clinicopathological and genetic correlates with ORACLE magnitude in the TRACERx exploratory cohort (n = 184 patients with stage I–III LUAD). A multiple linear model was applied separately for clinicopathological or genetic features (Methods). #Biopsy, number of biopsies. Each predictor is shown in the column with its model coefficient represented by color scales and labeled with significance (*P < 0.05, **P < 0.01, ***P < 0.005). For categorical variables including female, ex-smoker and smoker, stage II and stage III, the references are male, non-smoker and stage I, respectively. No correction was made for multiple comparisons. b, The OS association of six biomarkers identified in the TRACERx study14 was examined in the TRACERx exploratory cohort (n = 111 patients with stage I–III LUAD with all biomarker data available). Multivariable Cox analysis was performed on ORACLE, recent subclonal expansion, SCNA-ITH, subclonal WGD, detection of preoperative ctDNA status and STAS, adjusted for known clinicopathological risk factors. P values or baseline (Ref.) are shown for each predictor in the last column. The center box indicating HR and the error bars indicating 95% CIs are shown for each predictor on a natural log scale. c, The percentages of variation of survival outcome explained by the six TRACERx biomarkers were examined by a generalized linear model.